Here's what to do before and after getting lip fillers
What to apply to your lips after fillers
Right after your lip filler treatment, apply topical arnica to the injection sites. Arnica is a natural remedy known for its strong anti-inflammatory properties and ability to reduce bruising by promoting circulation and stimulating white blood cell activity. You can also take oral arnica tablets before and after your lip filler appointment to help minimize bruising.
If you do develop bruising, you need Alastin INhance Post-Injection Serum. It contains lactoferrin, a naturally-occurring protein that binds to iron receptors and helps to break up the blood cells in the skin that cause discoloration. Studies have shown that, when applied after injectable procedures like lip fillers, Alastin INhance reduced the intensity of discoloration caused by bruising by 73%.
What to avoid after lip fillers
Avoid anything that will cause heat for the first 48 hours after getting lip fillers. Heat increases blood flow and inflammation, which can worsen swelling and make bruising more likely after lip fillers. This includes:
No exercise, which increases body heat.
No hot showers. Use cool water to wash your face.
No hot drinks like coffee or tea.
Bottom line
Topical and oral arnica are the best things you can take and apply to your skin to help prevent bruising after lip fillers. You should also avoid anything that causes heat, which can increase swelling and bruising.
If you do develop bruising after fillers, use Alastin INhand Post-Procedure Serum, which has been clinically proven to significantly reduce post-procedure bruising.
I'm still on sabbatical and no longer run Baumann Cosmetic Institute, so please follow @SkinTypeSolutions on social media, or visit LeslieBaumannMD.com if you have questions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Medscape
26 minutes ago
- Medscape
Claims Data Fail to Accurately Identify MI Types
TOPLINE: Clinical auditing reveals significant misclassification in administrative codes for myocardial infarction (MI), with only 39% of type 1 (T1MI) codes and 72% of type 2 (T2MI) codes for the condition accurately reflecting the true diagnosis, researchers found. Nearly half of patients coded for T1MI had T2MI, whereas 26% of T2MI codes represented myocardial injury. METHODOLOGY: Researchers identified 350 randomly sampled patients with T1MI codes and 350 patients with T2MI codes during inpatient encounters using the International Statistical Classification of Diseases and Related Health Problems-10th Revision. The analysis included patients aged 65 years and older from October 1, 2017, to May 9, 2024, within eight hospitals in the Mass General Brigham system. Using the 4th Universal Definition of MI, the researchers reviewed the clinical encounters to assess evidence of plaque erosion or thrombus vs oxygen demand-supply imbalance. A second physician review was conducted for 146 challenging and 146 nonchallenging cases. TAKEAWAY: Among the 350 patients coded as having had T1MI, clinical adjudication revealed 138 (39%) as correctly diagnosed; 159 (45%) in fact had T2MI, and 35 (10%) had myocardial injury. Of the 350 patients coded as having had T2MI, 251 (72%) were confirmed, four (1%) were found to have T1MI, and 91 (26%) had myocardial injury. A second physician review demonstrated a high degree of agreement with the initial review, with a 94% agreement in nonchallenging cases and 86% in challenging cases. Hospitals equipped with vs without cardiac catheterization laboratories showed significantly lower misclassification rates (43% vs 58%; P = .0298). IN PRACTICE: 'Among individuals assigned a T1MI claims code, nearly one half have T2MI and many others have myocardial injury; fewer than one half have true T1MI,' the researchers reported. 'Our results also confirm and extend previous work showing that among those with T2MI codes, slightly more than one half have true T2MI, with most of the misclassification related to myocardial injury rather than T1MI. This has critically important implications for epidemiology and public policy' related to acute myocardial infarction. SOURCE: The study was led by Andrea Martinez, MD, of the Department of Medicine at Massachusetts General Hospital, Boston. It was published online on July 21 in Journal of the American College of Cardiology. LIMITATIONS: The results may not be generalized to other hospital systems and countries, where patterns of misclassification might differ. The researchers noted external validity assessment across multiple healthcare systems and in countries that have already introduced International Classification of Diseases-11th revision coding would be beneficial. While patterns of misclassification might have changed over time, the analysis was intentionally restricted to the period when codes for both T1MI and T2MI were available. DISCLOSURES: The study received support through a grant to Jason Wasfy from the Massachusetts General Hospital Executive Committee on Research. Individual authors reported receiving other grants and support, including grants from industry. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
29 minutes ago
- Yahoo
COVID-19 cases are on the rise in MA, CDC says. What to know about 'Nimbus' strain.
COVID-19 numbers are rising in Massachusetts, and in states across the country. "COVID-19 laboratory percent positivity is increasing nationally," according to the Centers for Disease Control and Prevention (CDC) website. "Emergency department visits for COVID-19 are increasing among young children 0-4 years old," though the CDC noted that emergency room visits are "low" overall. The latest COVID-19 strain is known as "Nimbus." Here's what to know. Are COVID-19 numbers increasing in Massachusetts? The CDC website has evaluated the issue in each state and determined cases in Massachusetts are likely rising. In Massachusetts, there is an 85.8% chance that COVID-19 numbers are increasing, according to the CDC. The Massachusetts Department of Public Health (DPH) reported that as of June 28, there were 377 confirmed cases of COVID and 77 unconfirmed cases. No COVID-19 deaths were reported at the time. The data stops in June because the Massachusetts DPH "ended data collection for the 2024-2025 viral respiratory season on June 28, 2025, and routine updates to their dashboard for the 2025-2026 season will resume later this summer." What is the current COVID-19 strain 'Nimbus?' As of early June, the new strain known as NB.1.8.1, or "Nimbus," made up 37% of COVID-19 cases nationwide. Variant NB.1.8.1 was first detected in China in January 2025 but accounted for about 0% of cases in the United States until May. The World Health Organization added at the time that currently approved COVID-19 vaccines are "expected to remain effective to this variant against symptomatic and severe disease." Virologists describe Nimbus as a 'slightly upgraded' version of its predecessor. While there is no evidence it causes more severe disease, it appears to be highly transmissible. What are the symptoms of Nimbus? Reported symptoms of NB.1.8.1 are similar to other COVID-19 strains, but one distinctive complaint is a severe sore throat, sometimes described as 'razor-blade throat fatigue.' Other symptoms may include: Mild cough Fever Muscle aches Nasal congestion Are vaccines still effective? Health experts say that updated COVID-19 vaccines remain the best protection against severe illness. Vaccination rates vary widely by state, and health officials continue to urge eligible individuals to stay current with their shots. How can people get tested? People can either take an at-home test or they can see their respective doctors. (This story was updated because an earlier version included an inaccuracy.) This article originally appeared on COVID cases on rise in MA, CDC says. What to know about latest strain Solve the daily Crossword
